Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Completed
University of British Columbia
Phase 4
2011-09-01
Subjects will be consented to the study prior to Coronary Artery Bypass Graft (CABG) and
randomly assigned to receive either ticagrelor 90 mg bid or placebo bid starting within 48
hours of surgery. Subjects will remain on study drug for a minimum of 12 months during which
time they will receive telephone follow-up one and nine months following CABG and clinic
visits three, six, and twelve months following CABG.
Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Completed
Cardiology Research UBC
Phase 4
2011-09-01
Subjects will be consented to the study prior to Coronary Artery Bypass Graft (CABG) and
randomly assigned to receive either ticagrelor 90 mg bid or placebo bid starting within 48
hours of surgery. Subjects will remain on study drug for a minimum of 12 months during which
time they will receive telephone follow-up one and nine months following CABG and clinic
visits three, six, and twelve months following CABG.
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Completed
Eli Lilly and Company
Phase 4
2012-03-01
This is a Phase 4, multicenter, open-label (blinded Pharmacodynamic PD results), randomized,
3-arm, parallel-design study of subjects with stable Coronary Artery Disease CAD. This study
will compare the PD effect of prasugrel 10 mg QD (once-daily) maintenance dose with
ticagrelor 90 mg BID (twice daily) maintenance dose in subjects with stable CAD who have
previously received ticagrelor loading does (LD) and maintenance dose (MD)..
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
